1,000th Patient Enrolls in Clinical Study Testing Infection Control Device

- Print  | 
TYRX, a company that commercializes implantable combination drug and device products for infection control, announced that the 1,000th patient has been enrolled in the Citadel & Centurion clinical studies.

Citadel & Centurion are multi-center studies that are evaluating the use of TYRX's AIGISRx Antibacterial Envelope in patients who are at high risk for cardiovascular implantable electronic devices infection. High-risk patients are those whose current CIED is being replaced with an implantable cardioverter-defibrillator or a cardiac resynchronization therapy device accompanied by the AIGISRx.

The AIGISRx Antibacterial Envelope is a mesh device that holds a pacemaker or implantable cardioverter-defibrillator in place and is coated with antibiotic agents to reduce infections.

More Articles on TYRX:

Study Reveals TYRX Antibacterial Envelope Helps Lower Infections From Cardiac Devices
TYRX Announces ICD-9 Code for AIGISRx Antibacterial Envelope

TYRX Launches New Patient Education Website

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.